OncoMatch/Clinical Trials/NCT05027776
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Is NCT05027776 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including 2-doses Group among 9-14 years and 3-doses Group among 9-19 years for hpv infections.
Treatment: 2-doses Group among 9-14 years · 3-doses Group among 9-19 years · 3-doses Group among 20-26 years — This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIA
Cervical Cancer Stage IIa
Demographics
Prior therapy
Cannot have received: HPV vaccine
Received marketed HPV vaccine or plan to receive marketed HPV vaccine during this study period or have enrolled in HPV vaccine clinical trials
Cannot have received: immune globulin or blood-related products
Receipt of immune globulin or blood-related products within 3 months; or plan to receive such products during this study period（month 0 to month 7）
Cannot have received: immunosuppressive treatment (long-term glucocorticoid)
Received immunosuppressive treatment within one month before study such as long-term glucocorticoid use(≥2mg per kg per day, lasted more than two wks), or plan to receive such treatment from month 0 to month 7
Cannot have received: inactivated, RNA, and recombinant vaccines
Receipt of inactivated, RNA, and recombinant vaccines within 14 days
Cannot have received: live vaccines
live vaccines within 28 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05027776 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HPV vaccine, immune globulin or blood-related products, immunosuppressive treatment disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIA is required.
Is there an age limit?
Yes. Patients must be 26 years or younger and at least 9 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages